Open Access
Review
Transforming Growth Factor β Signaling Pathway as a Potential Drug Target in Treating Aortic Diseases
Zijie Liu1, 2
, Tianyu Song3
, Liping Xie1, 2, 3, *
Author Information
Submitted: 16 Oct 2023 | Accepted: 20 Nov 2023 | Published: 18 Mar 2024
Abstract
The transforming growth factor β (TGF-β) signaling pathway is crucial for preserving the structural homeostasis of the aorta and promoting aortic development. This pathway encompasses both SMAD-dependent canonical pathway and SMAD-independent non-canonical signaling pathway. Heritable thoracic aortic aneurysms and dissection are highly correlated with genetic alterations in TGF-β canonical signaling-related genes. However, depending on the stage of the disease, the TGF-β signaling pathway can have either inhibitory or aggravation effects, making its roles in aortic disease complex and occasionally contradictory. This review aims to elucidate the biological mechanisms underlying the TGF-β signaling pathway in the most common aortic diseases, namely acute aortic syndromes and aortic aneurysms, and to evaluate the potential clinical application of TGF-β-targeting therapies in aortic diseases.
References
1.
Bossone, E.; Eagle, K.A. Epidemiology and management of aortic disease: aortic aneurysms and acute aortic syndromes. Nat. Rev. Cardiol. 2021, 18, 331‒348.
2.
Writing Committee, Members; Isselbacher, E.M.; Preventza, O.; et al. 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 2022, 80, e223‒e393.
3.
Juang, D.; Braverman, A.C.; Eagle, K. Cardiology patient pages. Aortic dissection. Circulation 2008, 118, e507‒e510.
4.
Schanzer, A.; Oderich, G.S. Management of Abdominal Aortic Aneurysms. N. Engl. J. Med. 2021, 385, 1690‒1698.
5.
Isselbacher, E.M. Thoracic and abdominal aortic aneurysms. Circulation 2005, 111, 816‒828.
6.
Gao, J.; Cao, H.; Hu, G.; et al. The mechanism and therapy of aortic aneurysms. Signal Transduct. Target. Ther. 2023, 8, 55.
7.
Li, J.; Pan, C.; Zhang, S.; et al. Decoding the Genomics of Abdominal Aortic Aneurysm. Cell 2018, 174, 1361‒1372.
8.
Francis, C.M.; Futschik, M.E.; Huang, J.; et al. Genome-wide associations of aortic distensibility suggest causality for aortic aneurysms and brain white matter hyperintensities. Nat. Commun. 2022, 13, 4505.
9.
Su, C.T.; Huang, J.W.; Chiang, C.K. Latent transforming growth factor binding protein 4 regulates transforming growth factor beta receptor stability. Hum. Mol. Genet. 2015, 24, 4024‒4036.
10.
Lan, H.C.; Li, H.J.; Lin, G.; et al. Cyclic AMP stimulates SF-1-dependent CYP11A1 expression through homeodomain-interacting protein kinase 3-mediated Jun N-terminal kinase and c-Jun phosphorylation. Mol. Cell. Biol. 2007, 27, 2027‒2036.
11.
Takeda, N.; Hara, H.; Fujiwara, T.; et al. TGF-β Signaling-Related Genes and Thoracic Aortic Aneurysms and Dissections. Int. J. Mol. Sci. 2018, 19, 2125.
12.
Ng, C.M.; Cheng, A.; Myers, L.A.; et al. TGF-beta-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome. J. Clin. Invest. 2004, 114, 1586‒1592.
13.
Neptune, E.R.; Frischmeyer, P.A.; Arking, D.E.; et al. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat. Genet. 2003, 3, 407‒411.
14.
Habashi, J.P.; Judge, D.P.; Holm, T.M.; et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 2006, 312, 117‒121.
15.
Chen, W.; Ten, Dijke, P. Immunoregulation by members of the TGFβ superfamily. Nat. Rev. Immunol. 2016, 16, 723‒740.
16.
Robertson, I.B.; Horiguchi, M.; Zilberberg, L.; et al. Latent TGF-β-binding proteins. Matrix Biol. 2015, 47, 44‒53.
17.
Meng, X.M.; Nikolic-Paterson, D.J.; Lan, H.Y. TGF-β: the master regulator of fibrosis. Nat. Rev. Nephrol. 2016, 12, 325‒338.
18.
Nolte, M.A.; Margadant, C. Controlling Immunity and Inflammation through Integrin-Dependent Regulation of TGF-β. Trends. Cell. Biol. 2020, 30, 833.
19.
Robertson, I.B.; Rifkin, D.B. Regulation of the Bioavailability of TGF-β and TGF-β-Related Proteins. Cold Spring Harb. Perspect. Biol. 2016, 8, a021907.
20.
Jenkins, G. The role of proteases in transforming growth factor-beta activation. Int. J. Biochem. Cell. Biol. 2008, 40, 1068‒1078.
21.
Derynck, R.; Zhang, Y.E. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003, 425, 577‒584.
22.
Chen, J.; Chang, R. Association of TGF-β Canonical Signaling-Related Core Genes with Aortic Aneurysms and Aortic Dissections. Front. Pharmacol. 2022, 13, 888563.
23.
Tie, Y.; Tang, F.; Peng, D.; et al. TGF-beta signal transduction: biology, function and therapy for diseases. Mol. Biomed. 2022, 3, 45.
24.
Tingting, T.; Wenjing, F.; Qian, Z.; et al. The TGF-β pathway plays a key role in aortic aneurysms. Clin. Chim. Acta. 2020, 501, 222‒228.
25.
van Dorst, D.C.H.; de Wagenaar, N.P.; van der Pluijm, I.; et al. Transforming Growth Factor-β and the Renin-Angiotensin System in Syndromic Thoracic Aortic Aneurysms: Implications for Treatment. Cardiovasc. Drugs Ther. 2021, 35, 1233‒1252.
26.
Shi, Y.; Massagué J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003, 113, 685‒700.
27.
Pardali, E.; Goumans, M.J.; ten Dijke, P. Signaling by members of the TGF-beta family in vascular morphogenesis and disease. Trends. Cell. Biol. 2010, 20, 556‒567.
28.
Goumans, M.J.; Liu, Z.; ten, Dijke P. TGF-beta signaling in vascular biology and dysfunction. Cell. Res. 2009, 19, 116‒127.
29.
Schlecht, A.; Leimbeck, S.V.; Jägle, H.; et al. Deletion of Endothelial Transforming Growth Factor-β Signaling Leads to Choroidal Neovascularization. Am. J. Pathol. 2017, 187, 2570‒2589.
30.
Li, W.; Li, Q.; Jiao, Y.; et al. Tgfbr2 disruption in postnatal smooth muscle impairs aortic wall homeostasis. J. Clin. Invest. 2014, 124, 755‒767.
31.
Wei, H.; Hu, J.H.; Angelov, S.N.; et al. Aortopathy in a Mouse Model of Marfan Syndrome Is Not Mediated by Altered Transforming Growth Factor β Signaling. J. Am. Heart. Assoc., 2017, 6, e004968.
32.
Hu, J.H.; Wei, H.; Jaffe, M.; et al. Postnatal Deletion of the Type II Transforming Growth Factor-β Receptor in Smooth Muscle Cells Causes Severe Aortopathy in Mice. Arterioscler. Thromb. Vasc. Biol. 2015, 35, 2647‒2656.
33.
Chen, P.Y.; Qin, L.; Li, G.; et al. Smooth Muscle Cell Reprogramming in Aortic Aneurysms. Cell Stem Cell 2020, 26, 542‒557
34.
van der Pluijm, I.; van Vliet, N.; von der Thusen, J.H.; et al. Defective Connective Tissue Remodeling in Smad3 Mice Leads to Accelerated Aneurysmal Growth Through Disturbed Downstream TGF-β Signaling. EbioMedicine 2016, 12, 280‒294.
35.
Dai, X.; Shen, J.; Annam, N.P.; et al. SMAD3 deficiency promotes vessel wall remodeling, collagen fiber reorganization and leukocyte infiltration in an inflammatory abdominal aortic aneurysm mouse model. Sci. Rep. 2015, 5, 10180.
36.
Zhang, P.; Hou, S.; Chen, J.; et al. Smad4 Deficiency in Smooth Muscle Cells Initiates the Formation of Aortic Aneurysm. Circ. Res. 2016, 118, 388‒399.
37.
Da, Ros F.; Carnevale, R.; Cifelli, G.; et al. Targeting Interleukin-1β Protects from Aortic Aneurysms Induced by Disrupted Transforming Growth Factor β Signaling. Immunity. 2017, 47, 959‒973.
38.
Huang, K.; Wang, Y.; Siu, K.L.; et al. Targeting feed-forward signaling of TGFβ/NOX4/DHFR/eNOS uncoupling/TGFβ axis with anti-TGFβ and folic acid attenuates formation of aortic aneurysms: Novel mechanisms and therapeutics. Redox. Biol. 2021, 38, 101757.
39.
Cook, J.R.; Clayton, N.P.; Carta, L.; et al. Dimorphic effects of transforming growth factor-β signaling during aortic aneurysm progression in mice suggest a combinatorial therapy for Marfan syndrome. Arterioscler. Thromb. Vasc. Biol. 2015, 35, 911‒917.
40.
Chen, X.; Rateri, D.L.; Howatt, D.A.; et al. TGF-β Neutralization Enhances AngII-Induced Aortic Rupture and Aneurysm in Both Thoracic and Abdominal Regions. PLoS One 2016, 11, e0153811.
41.
Doyle, A.J.; Redmond, E.M.; Gillespie, D.L.; et al. Differential expression of Hedgehog/Notch and transforming growth factor-β in human abdominal aortic aneurysms. J. Vasc. Surg. 2015, 62, 464‒470.
42.
Rush, C.; Nyara, M.; Moxon, J.V.; et al. Whole genome expression analysis within the angiotensin II-apolipoprotein E deficient mouse model of abdominal aortic aneurysm. BMC Genomics 2009, 10, 298.
43.
Angelov, S.N.; Hu, J.H.; Wei, H.; et al. TGF-β (Transforming Growth Factor-β) Signaling Protects the Thoracic and Abdominal Aorta From Angiotensin II-Induced Pathology by Distinct Mechanisms. Arterioscler. Thromb. Vasc. Biol. 2017, 37, 2102‒2113.
44.
Wang, Y.; Ait-Oufella, H.; Herbin, O.; et al. TGF-beta activity protects against inflammatory aortic aneurysm progression and complications in angiotensin II-infused mice. J. Clin. Invest. 2010, 120, 422‒432.
45.
Lareyre, F.; Clément, M.; Raffort, J.; et al. TGFβ (Transforming Growth Factor-β) Blockade Induces a Human-Like Disease in a Nondissecting Mouse Model of Abdominal Aortic Aneurysm. Arterioscler. Thromb. Vasc. Biol. 2017, 37, 2171‒2181.
46.
Meng, X.; Yang, J.; Zhang, K.; et al. Regulatory T cells prevent angiotensin II-induced abdominal aortic aneurysm in apolipoprotein E knockout mice. Hypertension 2014, 64, 875‒882.
47.
Dai, J.; Michineau S.; Franck, G.; et al. Long term stabilization of expanding aortic aneurysms by a short course of cyclosporine A through transforming growth factor-beta induction. PLoS One 2011, 6, e28903.
48.
Dai, J.; Losy, F.; Guinault, A.M.; et al. Overexpression of transforming growth factor-beta1 stabilizes already-formed aortic aneurysms: a first approach to induction of functional healing by endovascular gene therapy. Circulation 2005, 112, 1008‒1015.
49.
Frutkin, A.D.; Otsuka, G.; Stempien-Otero, A.; et al. TGF-[beta]1 limits plaque growth, stabilizes plaque structure, and prevents aortic dilation in apolipoprotein E-null mice. Arterioscler. Thromb. Vasc. Biol. 2009, 29, 1251‒1257.
50.
Bai, H.; Sun, P.; Wei, S.; et al. A novel intramural TGF β 1 hydrogel delivery method to decrease murine abdominal aortic aneurysm and rat aortic pseudoaneurysm formation and progression. Biomed. Pharmacother. 2021, 137, 111296.
51.
Bai, H.; Lee, J.S.; Hu, H.; et al. Transforming Growth Factor-β1 Inhibits Pseudoaneurysm Formation After Aortic Patch Angioplasty. Arterioscler. Thromb. Vasc. Biol. 2018, 38, 195‒205.
52.
Kojima, Y.; Werner, N.; Ye, J.; et al. Proefferocytic Therapy Promotes Transforming Growth Factor-β Signaling and Prevents Aneurysm Formation. Circulation 2018, 137, 750‒753.
53.
Golledge, J. Abdominal aortic aneurysm: update on pathogenesis and medical treatments. Nat. Rev. Cardiol. 2019, 16, 225‒242.
54.
Kim, M.K.; Ha, C.W.; In, Y.; et al. A Multicenter, Double-Blind, Phase III Clinical Trial to Evaluate the Efficacy and Safety of a Cell and Gene Therapy in Knee Osteoarthritis Patients. Hum. Gene. Ther. Clin. Dev. 2018, 29, 48‒59.
55.
Massagué, J.; Sheppard, D. TGF-β signaling in health and disease. Cell 2023, 186, 4007‒4037.
56.
Li, Z.; Kong, W. Cellular signaling in Abdominal Aortic Aneurysm. Cell. Signal. 2020, 70, 109575.
57.
Zhu, J.; Angelov, S.; Alp Yildirim, I.; et al. Loss of Transforming Growth Factor Beta Signaling in Aortic Smooth Muscle Cells Causes Endothelial Dysfunction and Aortic Hypercontractility. Arterioscler. Thromb. Vasc. Biol. 2021, 41, 1956‒1971.
58.
Zhou, D.; Feng, H.; Yang, Y.; et al. hiPSC Modeling of Lineage-Specific Smooth Muscle Cell Defects Caused by TGFBR1A230T Variant, and Its Therapeutic Implications for Loeys-Dietz Syndrome. Circulation 2021, 144, 1145‒1159.
59.
Gong, J.; Zhou, D.; Jiang, L.; et al. In Vitro Lineage-Specific Differentiation of Vascular Smooth Muscle Cells in Response to SMAD3 Deficiency: Implications for SMAD3-Related Thoracic Aortic Aneurysm. Arterioscler. Thromb. Vasc Biol., 2020, 40, 1651‒1663.
60.
Huang, X.; Yue, Z.; Wu, J.; et al. MicroRNA-21 Knockout Exacerbates Angiotensin II-Induced Thoracic Aortic Aneurysm and Dissection in Mice With Abnormal Transforming Growth Factor-β-SMAD3 Signaling. Arterioscler. Thromb. Vasc. Biol. 2018, 38, 1086‒1101.
61.
Wang, Y.; Liu, X.; Xu, Q.; et al. CCN2 deficiency in smooth muscle cells triggers cell reprogramming and aggravates aneurysm development. JCI Insight, 2023, 8, e162987.
62.
Ren, K.; Li, B.; Liu, Z.; et al. GDF11 prevents the formation of thoracic aortic dissection in mice: Promotion of contractile transition of aortic SMCs. J. Cell. Mol. Med. 2021, 25, 4623‒4636.
63.
Wang, Y.; Yin, P.; Chen, Y.H.; et al. A functional variant of SMAD4 enhances macrophage recruitment and inflammatory response via TGF-β signal activation in Thoracic aortic aneurysm and dissection. Aging 2018, 10, 3683‒3701.
64.
Holm, T.M.; Habashi, J.P.; Doyle, J.J.; et al. Noncanonical TGFβ signaling contributes to aortic aneurysm progression in Marfan syndrome mice. Science 2011, 332, 358‒361.
65.
Pedroza, A.J.; Koyano, T.; Trojan, J.; et al. Divergent effects of canonical and non-canonical TGF-β signalling on mixed contractile-synthetic smooth muscle cell phenotype in human Marfan syndrome aortic root aneurysms. J. Cell. Mol. Med. 2020, 24, 2369‒2383.
66.
Sinkala, M.; Nkhoma, P.; Mulder, N.; et al. Integrated molecular characterisation of the MAPK pathways in human cancers reveals pharmacologically vulnerable mutations and gene dependencies. Commun. Biol. 2021, 4, 9.
67.
Groeneveld, M.E.; van Burink, M.V.; Begieneman, M.P.; et al. Activation of extracellular signal-related kinase in abdominal aortic aneurysm. Eur. J. Clin. Invest. 2016, 46, 440‒447.
68.
Ghosh, A.; DiMusto, P.D.; Ehrlichman, L.K.; et al. The role of extracellular signal-related kinase during abdominal aortic aneurysm formation. J. Am. Coll. Surg. 2012, 215, 668‒680.
69.
Zhang, Y.; Naggar, J.C.; Welzig, C.M.; et al. Simvastatin inhibits angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E-knockout mice: possible role of ERK. Arterioscler. Thromb. Vasc. Biol. 2009, 29, 1764‒1771.
70.
Xiong, W.; Meisinger, T.; Knispel, R.; et al. MMP-2 regulates Erk1/2 phosphorylation and aortic dilatation in Marfan syndrome. Circ. Res. 2012, 110, e92‒e101.
71.
Habashi, J.P.; Doyle, J.J.; Holm, T.M.; et al. Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism. Science 2011, 332, 361‒365.
72.
Nettersheim, F.S.; Lemties, J.; Braumann, S.; et al. Nitro-oleic acid reduces thoracic aortic aneurysm progression in a mouse model of Marfan syndrome. Cardiovasc. Res. 2022, 118, 2211‒2225.
73.
Doyle, J.J.; Doyle, A.J.; Wilson, N.K.; et al. A deleterious gene-by-environment interaction imposed by calcium channel blockers in Marfan syndrome. Elife 2015, 4, e08648.
74.
Habashi, J.P.; MacFarlane, E.G.; Bagirzadeh, R.; et al. Oxytocin antagonism prevents pregnancy-associated aortic dissection in a mouse model of Marfan syndrome. Sci. Transl. Med. 2019, 11, eaat4822.
75.
Kugo, H.; Sukketsiri, W.; Iwamoto, K.; et al. Low glucose and serum levels cause an increased inflammatory factor in 3T3-L1 cell through Akt, MAPKs and NF-кB activation. Adipocyte 2021, 10, 232‒241.
76.
Yoshimura, K.; Aoki, H.; Ikeda, Y.; et al. Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase. Nat. Med. 2005, 11, 1330‒1338.
77.
Zhang, C.; Zhang, M.X.; Shen, Y.H.; et al. TNF-alpha suppresses prolyl-4-hydroxylase alpha1 expression via the ASK1-JNK-NonO pathway. Arterioscler. Thromb. Vasc. Biol. 2007, 27, 1760‒1767.
78.
Nakayama, A.; Nakayama, M.; Turner, C.J.; et al. Ephrin-B2 controls PDGFRβ internalization and signaling. Genes Dev. 2013, 27, 2576‒2589.
79.
Hiromi, T.; Yokoyama, U.; Kurotaki, D.; et al. Excessive EP4 Signaling in Smooth Muscle Cells Induces Abdominal Aortic Aneurysm by Amplifying Inflammation. Arterioscler, Thromb, Vasc, Biol. 2020, 40, 1559‒1573.
80.
Nakao, T.; Horie, T.; Baba, O.; et al. Genetic Ablation of MicroRNA-33 Attenuates Inflammation and Abdominal Aortic Aneurysm Formation via Several Anti-Inflammatory Pathways. Arterioscler. Thromb. Vasc. Biol. 2017, 37, 2161‒2170.
81.
Guo, Z.Z.; Cao, Q.A.; Li, Z.Z.; et al. SP600125 Attenuates Nicotine-Related Aortic Aneurysm Formation by Inhibiting Matrix Metalloproteinase Production and CC Chemokine-Mediated Macrophage Migration. Mediators. Inflamm. 2016, 2016, 9142425.
82.
Granata, A.; Serrano, F.; Bernard, W.G.; et al. An iPSC-derived vascular model of Marfan syndrome identifies key mediators of smooth muscle cell death. Nat. Genet. 2017, 49, 97‒109.
83.
Gao, P.; Gao, P.; Zhao, J.; et al. MKL1 cooperates with p38MAPK to promote vascular senescence, inflammation, and abdominal aortic aneurysm. Redox. Biol. 2021, 41, 101903.
84.
Ortega, R.; Collado, A.; Selles, F.; et al. SGLT-2 (Sodium-Glucose Cotransporter 2) Inhibition Reduces Ang II (Angiotensin II)-Induced Dissecting Abdominal Aortic Aneurysm in ApoE (Apolipoprotein E) Knockout Mice. Arterioscler. Thromb. Vasc. Biol. 2019, 39, 1614‒1628.
85.
Davis, F.M.; Tsoi, L.C.; Melvin, W.J.; et al. Inhibition of macrophage histone demethylase JMJD3 protects against abdominal aortic aneurysms. J. Exp. Med. 2021, 218, e20201839.
86.
Wang, Q.; Ding, Y.; Song, P.; et al. Tryptophan-Derived 3-Hydroxyanthranilic Acid Contributes to Angiotensin II-Induced Abdominal Aortic Aneurysm Formation in Mice In Vivo. Circulation 2017, 136, 2271‒2283.
87.
Wu, G.; Chen, T.; Shahsafaei, A.; et al. Complement regulator CD59 protects against angiotensin II-induced abdominal aortic aneurysms in mice. Circulation 2010, 121, 1338‒1346.
88.
Ijaz, T.; Sun, H.; Pinchuk, I.V.; et al. Deletion of NF-κB/RelA in Angiotensin II-Sensitive Mesenchymal Cells Blocks Aortic Vascular Inflammation and Abdominal Aortic Aneurysm Formation. Arterioscler. Thromb. Vasc. Biol. 2017, 37, 1881‒1890.
89.
Liu, C.L.; Liu, X.; Zhang, Y.; et al. Eosinophils Protect Mice from Angiotensin-II Perfusion-Induced Abdominal Aortic Aneurysm. Circ. Res., 2021, 128, 188‒202.
90.
You, W.; Hong, Y.; He, H.; et al. TGF-β mediates aortic smooth muscle cell senescence in Marfan syndrome. Aging 2019, 11, 3574‒3584.
91.
Chen, H.Z.; Wang, F.; Gao, P.; et al. Age-Associated Sirtuin 1 Reduction in Vascular Smooth Muscle Links Vascular Senescence and Inflammation to Abdominal Aortic Aneurysm. Circ. Res. 2016, 119, 1076‒1088.
92.
Zhong, L.; He, X.; Si, X.; et al. SM22α (Smooth Muscle 22α) Prevents Aortic Aneurysm Formation by Inhibiting Smooth Muscle Cell Phenotypic Switching Through Suppressing Reactive Oxygen Species/NF-κB (Nuclear Factor-κB). Arterioscler. Thromb. Vasc. Biol., 2019, 39, e10‒e25.
93.
Chen, J.; Peters, A.; Papke, C.L.; et al. Loss of Smooth Muscle α-Actin Leads to NF-κB-Dependent Increased Sensitivity to Angiotensin II in Smooth Muscle Cells and Aortic Enlargement. Circ. Res. 2017, 120, 1903‒1915.
94.
Liang, E.S.; Bai, W.W.; Wang, H.; et al. PARP-1 (Poly[ADP-Ribose] Polymerase 1) Inhibition Protects From Ang II (Angiotensin II)-Induced Abdominal Aortic Aneurysm in Mice. Hypertension 2018, 72, 1189‒1199.
95.
Isselbacher, E.M.; Lino Cardenas, C.L.; Lindsay, M.E. Hereditary Influence in Thoracic Aortic Aneurysm and Dissection. Circulation 2016, 133, 2516‒2528.
96.
Braverman, A.C. Heritable thoracic aortic aneurysm disease: recognizing phenotypes, exploring genotypes. J. Am. Coll. Cardiol. 2015, 65, 1337‒1339.
97.
Fletcher, A.J.; Syed, M.B.J.; Aitman, T.J.; et al. Inherited Thoracic Aortic Disease: New Insights and Translational Targets. Circulation 2020, 141, 1570‒1587.
98.
Carta, L.; Smaldone, S.; Zilberberg, L.; et al. p38 MAPK is an early determinant of promiscuous Smad2/3 signaling in the aortas of fibrillin-1 (Fbn1)-null mice. J. Biol. Chem. 2009, 284, 5630‒5636.
99.
Park, J.H.; Kim, M.S.; Ham, S.; et al. Transforming Growth Factor β Receptor Type I Inhibitor, Galunisertib, Has No Beneficial Effects on Aneurysmal Pathological Changes in Marfan Mice. Biomol. Ther. 2020, 28, 98‒103.
100.
Da, X.; Li, Z.; Huang, X.; et al. AGGF1 therapy inhibits thoracic aortic aneurysms by enhancing integrin α7-mediated inhibition of TGF-β1 maturation and ERK1/2 signaling. Nat. Commun. 2023, 14, 2265.
101.
Arce, C.; Rodríguez-Rovira, I.; De Rycke, K.; et al. Anti-TGFβ (Transforming Growth Factor β) Therapy with Betaglycan-Derived P144 Peptide Gene Delivery Prevents the Formation of Aortic Aneurysm in a Mouse Model of Marfan Syndrome. Arterioscler. Thromb. Vasc. Biol. 2021, 41, e440‒e452.
102.
Huang, T.H.; Chang, H.H.; Guo, Y.R.; et al. Vitamin B Mitigates Thoracic Aortic Dilation in Marfan Syndrome Mice by Restoring the Canonical TGF-β Pathway. Int. J. Mol. Sci. 2021, 22, 11737.
103.
Lim, W.W.; Dong, J.; Ng, B.; et al. Inhibition of IL11 Signaling Reduces Aortic Pathology in Murine Marfan Syndrome. Circ. Res. 2022, 130, 728‒740.
104.
Ng, B.; Dong, J.; D’Agostino, G.; et al. Interleukin-11 is a therapeutic target in idiopathic pulmonary fibrosis. Sci. Transl. Med. 2019, 11, eaaw1237.
105.
Schafer, S.; Viswanathan, S.; Widjaja, A.A.; et al. IL-11 is a crucial determinant of cardiovascular fibrosis. Nature 2017, 552, 110‒115.
106.
MacCarrick, G.; Black, J.H.3rd.; Bowdin, S.; et al. Loeys-Dietz syndrome: a primer for diagnosis and management. Genet. Med. 2014, 16, 576‒587.
107.
Lindsay, M.E.; Schepers, D.; Bolar, N.A.; et al. Loss-of-function mutations in TGFB2 cause a syndromic presentation of thoracic aortic aneurysm. Nat. Genet. 2012, 44, 922‒927.
108.
Bertoli-Avella, A.M.; Gillis, E.; Morisaki, H.; et al. Mutations in a TGF-β ligand, TGFB3, cause syndromic aortic aneurysms and dissections. J. Am. Coll. Cardiol. 2015, 65, 1324‒1336.
109.
Loeys, B.L.; Chen, J.; Neptune, E.R.; et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat. Genet. 2005, 37, 275‒281.
110.
Loeys, B.L.; Schwarze, U.; Holm, T.; et al. Aneurysm syndromes caused by mutations in the TGF-beta receptor. N. Engl. J. Med. 2006, 355, 788‒798.
111.
van de Laar, I.M.; Oldenburg, R.A.; Pals, G.; et al. Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis. Nat. Genet. 2011, 43, 121‒126.
112.
Cannaerts, E.; Kempers, M.; Maugeri, A.; et al. Novel pathogenic SMAD2 variants in five families with arterial aneurysm and dissection: further delineation of the phenotype. J. Med. Genet. 2019, 56, 220‒227.
113.
Boileau, C.; Guo, D.C.; Hanna, N.; et al. TGFB2 mutations cause familial thoracic aortic aneurysms and dissections associated with mild systemic features of Marfan syndrome. Nat. Genet. 2012, 44, 916‒921.
114.
Akhurst, R.J. The paradoxical TGF-β vasculopathies. Nat. Genet. 2012, 44, 838‒839.
115.
Schepers, D.; Tortora, G.; Morisaki, H.; et al. A mutation update on the LDS-associated genes TGFB2/3 and SMAD2/3. Hum. Mutat. 2018, 39, 621‒634.
116.
Ostberg, N.P.; Zafar, M.A.; Ziganshin, B.A.; et al. The Genetics of Thoracic Aortic Aneurysms and Dissection: A Clinical Perspective. Biomolecules 2020, 10, 182.
117.
Velchev, J.D.; Van Laer, L.; Luyckx, I.; et al. Loeys-Dietz Syndrome. Adv. Exp. Med. Biol. 2021, 1348, 251‒264.
118.
Liu, S.; Ren, J.; Ten Dijke, P. Targeting TGFβ signal transduction for cancer therapy. Signal Transduct. Target. Ther. 2021, 6, 8.
119.
Lacouture, M.E.; Morris, J.C.; Lawrence, D.P.; et al. Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor β by the monoclonal antibody fresolimumab (GC1008). Cancer Immunol. Immunother. 2015, 64, 437‒446.
Issue
Volume 3, Issue 1How to Cite
Liu, Z., Song, T., & Xie, L. (2024). Transforming Growth Factor β Signaling Pathway as a Potential Drug Target in Treating Aortic Diseases. International Journal of Drug Discovery and Pharmacology, 3(1), 100003. https://doi.org/10.53941/ijddp.2024.100003
RIS
BibTex
Copyright & License
Copyright (c) 2024 by the authors.
This work is licensed under a This work is licensed under a Creative Commons Attribution 4.0 International License.